175 related articles for article (PubMed ID: 18760876)
1. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
2. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
3. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
4. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
Dadmarz R; Bockstoce DC; Golub SH
Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
[TBL] [Abstract][Full Text] [Related]
6. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
Espevik T; Figari IS; Ranges GE; Palladino MA
J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
9. IFN-beta 2/IL-6 augments the activity of human natural killer cells.
Luger TA; Krutmann J; Kirnbauer R; Urbanski A; Schwarz T; Klappacher G; Köck A; Micksche M; Malejczyk J; Schauer E
J Immunol; 1989 Aug; 143(4):1206-9. PubMed ID: 2787359
[TBL] [Abstract][Full Text] [Related]
10. Regulation of NK cell functions by TGF-beta 1.
Bellone G; Aste-Amezaga M; Trinchieri G; Rodeck U
J Immunol; 1995 Aug; 155(3):1066-73. PubMed ID: 7636180
[TBL] [Abstract][Full Text] [Related]
11. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
[TBL] [Abstract][Full Text] [Related]
12. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
13. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity.
Geldhof AB; Raes G; Bakkus M; Devos S; Thielemans K; De Baetselier P
Cancer Res; 1995 Jul; 55(13):2730-3. PubMed ID: 7540948
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
Kuramitsu Y
Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
[TBL] [Abstract][Full Text] [Related]
15. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.
Rook AH; Kehrl JH; Wakefield LM; Roberts AB; Sporn MB; Burlington DB; Lane HC; Fauci AS
J Immunol; 1986 May; 136(10):3916-20. PubMed ID: 2871107
[TBL] [Abstract][Full Text] [Related]
16. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
Pappo I; Tahara H; Robbins PD; Gately MK; Wolf SF; Barnea A; Lotze MT
J Surg Res; 1995 Feb; 58(2):218-26. PubMed ID: 7861776
[TBL] [Abstract][Full Text] [Related]
17. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
Hill LL; Perussia B; McCue PA; Korngold R
Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
[TBL] [Abstract][Full Text] [Related]
18. A functional comparison of tumor cell killing by activated macrophages and natural killer cells.
Roder JC; Lohmann-Matthes ML; Domzig W; Kiessling R; Haller O
Eur J Immunol; 1979 Apr; 9(4):283-8. PubMed ID: 467492
[TBL] [Abstract][Full Text] [Related]
19. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells.
Gunji Y; Gorelik E
Cancer Res; 1988 Sep; 48(18):5216-21. PubMed ID: 3409246
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
